Cancer Immunotherapy and Biomarkers

This study presents an eco-evolutionary model showing how tumor mutational burden influences immunotherapy success and resistance through trade-offs between oncogenic and immunogenic mutations.

This study shows that the anti-B7-H3 antibody MJ18 does not bind B7-H3 but instead binds FcγRIIB and fails to induce tumor regression in murine models.

The paper introduces AlphaTMB, a composite biomarker combining tumor mutation burden with pathogenicity scores, showing improved survival prediction in immunotherapy response.

This study identifies HOXD13 as a driver of a developmental program in melanoma that promotes angiogenesis and suppresses T-cell infiltration through a gene regulatory axis involving VEGFA, SEMA3A, and CD73.

The paper shows that CMTM6 suppresses FAS expression in mice but not humans, highlighting species differences in CMTM6-FAS interaction.

The paper identifies CD14+CD4+ T cells in NSCLC tumor microenvironment driven by TNF, linked to poor patient survival.

This study uses multi-omics profiling to show that house dust mite exposure accelerates lung tumor growth through immune-mediated mechanisms by altering the tumor microenvironment.

NeoPrecis improves immunotherapy response prediction by integrating immunogenicity and clonality-aware neoantigen landscapes, showing better performance than tumor mutation burden in melanoma and NSCLC.

The paper shows that SFB colonization enhances anti-PD-1 therapy efficacy against antigen-sharing tumors by promoting T cell plasticity and immune control.

The paper identifies IL-15 and TNFSF9 as ligands promoting γδ T cell effector function in CRC using single-cell RNA-seq and in silico perturbation analysis.

This paper introduces a live tumor fragment platform to assess immunotherapy response in core needle biopsies, showing it can detect T-cell responses and mitigate tissue heterogeneity challenges.

The paper identifies CHD1 and MAP3K7 as mediators of cancer immunotherapy resistance through CRISPR screens and shows their potential as biomarkers for immunotherapy response.

This study examines serum oxylipin profiles in melanoma subtypes and immunotherapy responders to identify potential metabolic biomarkers for treatment response.

This study shows VISTA interacts with its ligands in cis, not trans, due to its membrane orientation, and finds a correlation between VISTA and PSGL-1 in cancer data.

This study compares immune infiltration in ICI-induced lichen planus and non-drug-related lichen planus, finding reduced T-cell infiltration and increased B-cell frequency in the former.

The paper investigates immune cell senescence in melanoma patients and finds that non-responders to immunotherapy have higher senescence in immune cells compared to responders.

This study shows dietary restriction enhances CD8+ T cell ketolysis, improving mitochondrial function and anti-tumor immunity by reducing exhaustion.

This study shows that B-cell depletion or TIM-1 targeting enhances immunotherapy efficacy in HCC by reducing B-cell-mediated immunosuppression and improving antigen presentation.

This study identifies metabolic biomarkers predictive of immune checkpoint inhibitor response in gynecologic cancers using flux balance analysis and machine learning.

This study shows that combining SUMO E1 inhibition with TIGIT blockade enhances anti-tumor immunity in pancreatic cancer by reducing regulatory T cells and improving T cell reactivity.

This study shows that inhibiting Neuropilin-1 slows B16-F10 melanoma progression and reduces Treg-mediated immunosuppression.

This study examines how checkpoint receptors in circulating γδ T cells correlate with cancer immunotherapy outcomes, identifying potential prognostic markers and therapeutic targets.

The paper models PD-L1 dynamics in response to immunotherapy, showing that PD-L1 upregulation leads to treatment failure, while PD-1/PD-L1 blockade improves anti-tumor responses.

This study identifies PD-1's role in maintaining stem-like CD8+ T cells through TCR affinity regulation and signaling fine-tuning, showing its impact on immunotherapy efficacy.

This study identifies pre-treatment naive CD4+ T cell abundance as a predictor of severe irAEs in patients receiving anti-PD-1/CTLA4 checkpoint inhibitor therapy for melanoma.

The paper introduces TCPGdb, a database integrating T cell perturbation screens to identify critical regulators of T cell function and anti-tumor persistence.

This study shows that hematopoietic Tet2 inactivation improves immune checkpoint blockade response in mice and is associated with better clinical outcomes in melanoma patients with TET2-driven clonal hematopoiesis.

This study identifies risk factors and patterns of immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors using real-world data.